237 related articles for article (PubMed ID: 30614347)
21. Clinical experiences with testosterone therapy: prostate safety.
Ebert T
Aging Male; 2004 Dec; 7(4):304-11. PubMed ID: 15799126
[TBL] [Abstract][Full Text] [Related]
22. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
Ebert T; Jockenhövel F; Morales A; Shabsigh R
Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
[TBL] [Abstract][Full Text] [Related]
23. Testosterone treatment in the aging male: myth or reality?
Nigro N; Christ-Crain M
Swiss Med Wkly; 2012; 142():w13539. PubMed ID: 22430839
[TBL] [Abstract][Full Text] [Related]
24. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
Kaufman JM; Graydon RJ
J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
[TBL] [Abstract][Full Text] [Related]
25. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
[TBL] [Abstract][Full Text] [Related]
26. Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication.
Qin X; Zhang H; Ye D; Yao X; Zhang S; Dai B
Andrology; 2013 May; 1(3):512-6. PubMed ID: 23536478
[TBL] [Abstract][Full Text] [Related]
27. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
28. Is testosterone a friend or a foe of the prostate?
Jannini EA; Gravina GL; Morgentaler A; Morales A; Incrocci L; Hellstrom WJ
J Sex Med; 2011 Apr; 8(4):946-55. PubMed ID: 21457469
[TBL] [Abstract][Full Text] [Related]
29. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men.
Almeida OP; Waterreus A; Spry N; Flicker L; Martins RN
Psychoneuroendocrinology; 2004 Sep; 29(8):1071-81. PubMed ID: 15219659
[TBL] [Abstract][Full Text] [Related]
30. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
[TBL] [Abstract][Full Text] [Related]
31. Dynamic Patterns of Testosterone Levels in Individuals and Risk of Prostate Cancer among Hypogonadal Men: A Longitudinal Study.
Xu X; Zhang X; Zhong Y; Saad F; Perez-Patron MJ; Haider K; Haider A
J Urol; 2018 Feb; 199(2):465-473. PubMed ID: 28941925
[TBL] [Abstract][Full Text] [Related]
32. Testosterone and prostate cancer: what are the risks for middle-aged men?
Morgentaler A
Urol Clin North Am; 2011 May; 38(2):119-24. PubMed ID: 21621078
[TBL] [Abstract][Full Text] [Related]
33. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
Morales A; Black AM; Emerson LE
BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
[TBL] [Abstract][Full Text] [Related]
34. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.
Morote J; Ramirez C; Gómez E; Planas J; Raventós CX; de Torres IM; Catalán R
BJU Int; 2009 Aug; 104(4):486-9. PubMed ID: 19220251
[TBL] [Abstract][Full Text] [Related]
35. Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
Morgentaler A
J Urol; 2013 Jan; 189(1 Suppl):S26-33. PubMed ID: 23234627
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
37. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer.
Teloken C; Da Ros CT; Caraver F; Weber FA; Cavalheiro AP; Graziottin TM
J Urol; 2005 Dec; 174(6):2178-80. PubMed ID: 16280759
[TBL] [Abstract][Full Text] [Related]
38. Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate.
Walsh PC; Siiteri PK
J Urol; 1975 Aug; 114(2):254-6. PubMed ID: 125803
[TBL] [Abstract][Full Text] [Related]
39. Androgens and prostate cancer risk.
Wirén S; Stattin P
Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):601-13. PubMed ID: 18971121
[TBL] [Abstract][Full Text] [Related]
40. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth.
Krakowsky Y; Morgentaler A
Eur Urol Focus; 2019 Jan; 5(1):81-89. PubMed ID: 28753828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]